clinical trial · NCT02216214
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
Astellas Pharma Global Development, Inc.·phase4·completed·n = 888
Overactive Bladder (OAB)MirabegronPlacebo
brief summary
The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.
started
Oct 7, 2014
primary completion
Nov 29, 2017
completion
Jan 2, 2018
last updated
Nov 22, 2024
official title
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol